Abstract
In Taiwan, hematopoietic SCT (HSCT) has been used to treat patients with hematological diseases since 1983. Since then, more than 2200 patients have undergone HSCT in 15 large hospitals. The disease entities included acute leukemia in 37% of cases, non-Hodgkin's lymphoma in 26%, CML in 10%, multiple myeloma in 7% and severe aplastic anemia in 6%. The conditioning regimens used were mainly myeloablative (84% of cases). Non-myeloablative regimens were fludarabine-based. The average age of allogeneic recipients was at least 10 years older than those in the era before their application. The grafts of all patients were derived from peripheral blood in 85% of cases, BM in 13% and cord blood (CB) in 2%. Forty percent of HSCT patients received autologous grafts, whereas more than 25% of allogeneic HSCT patients received grafts from unrelated donors, and overall, there were more than 200 Taiwan HSCT recipients. Currently, CB has been used successfully in pediatric patients with thalassemia major and also in adult patients with hematological malignancy. After transplantation, there was a relatively lower prevalence of acute GVHD. However, a relatively higher proportion of hepatitis B carriers in the recipients had led to a higher inciden...Continue Reading
References
Apr 1, 1990·Transplantation·P M ChenC H Tzeng
Aug 1, 1996·Transfusion·C H TzengP M Chen
Feb 1, 1997·Transfusion·C H TzengY R Chen
Apr 28, 1999·Bone Marrow Transplantation·C K ShawW P Tseng
Jun 29, 1999·Transplantation·P M ChenJ H Liu
Sep 11, 2001·Bone Marrow Transplantation·S C KuP C Yang
Feb 13, 2002·Bone Marrow Transplantation·G-Y HungB Hwang
Nov 15, 2002·International Journal of Hematology·Tsung Dao Lee
Oct 8, 2003·Annals of Hematology·L Y BaiP M Chen
Jan 19, 2005·European Journal of Haematology·M Y LeeP M Chen
Apr 23, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Tang-Her JaingRobert Chow
Aug 30, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Say-Bee PohPo-Min Chen
Sep 9, 2005·International Journal of Hematology·Giun-Yi HungBetau Hwanga
Jan 10, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Liang-Tsai HsiaoPo-Min Chen
Jun 19, 2007·Bone Marrow Transplantation·T-H JaingR Chow
Citations
Mar 2, 2010·Bone Marrow Transplantation·A YoshimiUNKNOWN Asia-Pacific Blood and Marrow Transplantation Group (APBMT)
Jul 31, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Tso-Fu WangRuey-Ho Kao
Jan 20, 2015·Bone Marrow Transplantation·A A HamidiehA Ghavamzadeh
Oct 15, 2014·British Journal of Cancer·S-H ChienC-H Tzeng
Feb 15, 2017·PloS One·Po-Shen KoJin-Hwang Liu
Aug 15, 2009·Current Opinion in Hematology·Alois Gratwohl, Helen Baldomero
Nov 30, 2018·JAMA Oncology·Tzu-Chuan HuangYi-Ying Wu
May 10, 2013·PloS One·Yi-Kung LeeYung-Cheng Su
Aug 21, 2014·Cancer Nursing·Yu-Ping HuangHui-Min Chih
Apr 20, 2017·Oncotarget·Jiun-Nong LinJi-An Liang
Dec 16, 2010·European Journal of Haematology·Yao-Yu HsiehChun-Yu Liu